Baxter International Inc. (NYSE:BAX) is scheduled to announce its earnings results before the market opens on Wednesday, October 25th. Analysts expect the company to announce earnings of $0.59 per share for the quarter. Baxter International has set its Q3 guidance at $0.58-0.60 EPS and its FY17 guidance at $2.34-2.40 EPS.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.06. Baxter International had a net margin of 8.85% and a return on equity of 14.82%. The company had revenue of $2.61 billion for the quarter, compared to the consensus estimate of $2.59 billion. During the same quarter in the prior year, the firm earned $0.46 earnings per share. The company’s revenue for the quarter was up .8% compared to the same quarter last year. On average, analysts expect Baxter International to post $2.39 EPS for the current fiscal year and $2.67 EPS for the next fiscal year.

Shares of Baxter International Inc. (NYSE BAX) opened at 63.92 on Wednesday. The firm has a 50 day moving average of $62.89 and a 200 day moving average of $59.41. The stock has a market cap of $34.83 billion, a P/E ratio of 38.79 and a beta of 0.65. Baxter International Inc. has a one year low of $43.13 and a one year high of $64.75.

In related news, Director Thomas T. Stallkamp sold 8,920 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $62.28, for a total transaction of $555,537.60. Following the completion of the sale, the director now directly owns 16,263 shares in the company, valued at $1,012,859.64. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Giuseppe Accogli sold 12,670 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $60.96, for a total transaction of $772,363.20. Following the sale, the senior vice president now owns 33,286 shares of the company’s stock, valued at $2,029,114.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,050 shares of company stock valued at $2,158,587. 0.05% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at

Several research firms have recently weighed in on BAX. Cowen and Company set a $68.00 price objective on shares of Baxter International and gave the company a “hold” rating in a research report on Sunday. Cantor Fitzgerald set a $70.00 target price on shares of Baxter International and gave the stock a “buy” rating in a report on Wednesday, July 26th. Citigroup Inc. assumed coverage on shares of Baxter International in a report on Thursday, August 17th. They issued a “neutral” rating and a $63.00 target price for the company. Zacks Investment Research cut shares of Baxter International from a “buy” rating to a “hold” rating in a report on Monday. Finally, Leerink Swann reiterated an “outperform” rating and issued a $75.00 target price (up from $67.00) on shares of Baxter International in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $65.69.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Earnings History for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with's FREE daily email newsletter.